Published in

Open Science Framework, 2022

DOI: 10.17605/osf.io/ys9rv

Links

Tools

Export citation

Search in Google Scholar

Effect of ACBP/DBI on the risk of age-related diseases

Journal article published in 2022 by Adrien Joseph ORCID, Guido Kroemer
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Question mark in circle
Preprint: policy unknown
Question mark in circle
Postprint: policy unknown
Question mark in circle
Published version: policy unknown

Abstract

Acyl-coenzyme A binding protein (ACBP), also called diazepam-binding inhibitor (DBI) is a phylogenetically ancient protein that participates in paracrine and neuroendocrine signaling. Intriguingly, knockout of ACBP/DBI orthologues in yeast or nematodes increases lifespan, suggesting that the protein may have pro-aging effects, a conjecture that has not yet been investigated in vertebrates. Of note, in mice and human cells, ACBP/DBI inhibits autophagy, which is a well-studied antiaging mechanism. We previously showed that ACBP/DBI correlates with BMI, but also with age, and that these two correlations were independent. In this study, we plan to investigate the role of ACBP/DBI on age-related diseases such as cancer and cardiovascular diseases in humans from the DESIR cohort, a longitudinal cohort that recruited 5212 outpatients from the Loire valley between 1994 and 2010 with longitudinal follow-up every 3 years.